<Blinded Review: TIME_ANON_0966>
**Composite Score:** 5.6 / 10.0 (Rigor: 1.8/3.5 | Claims: 1.3/2.5 | Biology: 1.3/2.0 | Reproducibility: 1.2/2.0)
**Bias Category:** Technical/Assay
**Verdict:** Major Revision
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Mid-Stage High-Throughput
**Epistemic Stage:** Basic/Mechanistic Discovery

OVERALL_SCORE: 5.6/10
VERDICT: CAVEATS
ESTIMATED_DECADE: 2020s

---

### 1. Executive Summary / SUMMARY
This epigenetic pharmacology study examines the effects of curcumin (`Cur`) and its metabolically stable synthetic analog dimethoxycurcumin (`DMC`) on ten-eleven translocation (`TET1`, `TET2`, `TET3`) enzyme expression and catalytic activity, global 5-hydroxymethylcytosine (`5hmC`) levels, and single-CpG genome-wide `5hmC` profiles in human myeloid leukemia cell lines (`U937` and `HL60`). Using fluorometric ELISA-like kits (`Epigentek` global `5hmC` and `Abcam` nuclear extract `TET` activity), one-step `qRT-PCR` (`TET1/2/3` normalized to `GAPDH` at 24 h and 48 h), and reduced representation oxidative bisulfite sequencing (`oxRRBS`, `NuGEN Ovation RRBS Methyl-Seq` splitting DNA into mock `BS` [measuring $5\text{mC} + 5\text{hmC}$] and oxidative `oxBS` [measuring $5\text{mC}$ alone] across 288,097 common CpGs via `Bismark` and `methylKit`), the authors report that curcumin (`5 uM`) and `DMC` (`1 uM` and `2 uM`) increase `TET1/2/3` mRNA and nuclear `TET` activity, elevate global `5hmC`, and induce both locus-specific `5hmC` gains (194 gene promoters for `Cur`, 173 for `DMC`) and `5hmC` losses (154 gene promoters for `Cur`, 171 for `DMC`).

While applying paired mock-BS and oxidative-BS (`oxRRBS`) to distinguish `5hmC` from `5mC` is technically appropriate in principle, forensic audit reveals **a fundamental conceptual flaw in equating any decrease in `5hmC` ($\Delta 5\text{hmC} < 0$) with "active demethylation" without examining whether $5\text{mC}$ or total modification ($5\text{mC} + 5\text{hmC}$) actually decreased, alongside a missing mathematical formula in Section 4.5, absence of replicate structure or negative-value filtering disclosure in the `mock - oxBS` subtraction, and no public sequencing data deposition (`GEO`/`SRA`)**.

### 2. Methodological & Statistical Audit / STRENGTHS & WEAKNESSES & METHODOLOGICAL AUDIT

#### Major Methodological & Conceptual Flaws
1. **Conceptual Fallacy: Equating Any Decrease in `5hmC` ($\Delta 5\text{hmC} < 0$) with "Active Demethylation" Without Checking `5mC` (`oxBS`) or Unmodified Cytosine Levels:**
   - Throughout the Abstract, Results (lines 60, 63, 70–77, `Tables 1–2`), and Discussion, the authors define **every single CpG site or promoter where $5\text{hmC}$ decreased relative to untreated control ($\Delta 5\text{hmC} < 0$) as "active demethylation"**!
   - **Audit:** At any given CpG site, cytosine exists in three major states: unmodified cytosine ($C$), 5-methylcytosine ($5\text{mC}$, measured directly by `oxBS`), and 5-hydroxymethylcytosine ($5\text{hmC} = \text{BS} - \text{oxBS}$). A decrease in $5\text{hmC}$ ($\Delta 5\text{hmC} < 0$) can occur via two opposite pathways:
     1. **True Active/Passive Demethylation ($5\text{hmC} \to 5\text{fC}/5\text{caC} \to C$):** $5\text{hmC}$ decreases AND total modified cytosine ($\text{BS} = 5\text{mC} + 5\text{hmC}$) decreases (so unmodified $C$ increases).
     2. **De Novo Methylation or Impaired `TET` Oxidation ($C \to 5\text{mC}$ or failure to oxidize $5\text{mC} \to 5\text{hmC}$):** $5\text{hmC}$ decreases while $5\text{mC}$ (`oxBS`) *increases* or remains high!
   - Despite having both the `mock BS` ($5\text{mC} + 5\text{hmC}$) and `oxBS` ($5\text{mC}$) datasets in hand, the authors **never report $\Delta 5\text{mC}$ or $\Delta(5\text{mC} + 5\text{hmC})$** for the sites and promoters in `Figures 4, 6` and `Tables 1, 2`, nor do they measure mRNA expression of any of the putative "actively demethylated" genes in `Tables 1–2`! Calling a drop in $5\text{hmC}$ "active demethylation" without verifying that unmodified cytosine ($C = 1 - \text{BS}$) actually increased is biochemically invalid.
2. **Statistical Noise and Negative-Estimate Artifacts in Direct Subtraction (`mock BS - oxBS`) Without Joint ML Modeling (`MLML` / `oxBS-MLE`):**
   - In Section 4.7 (line 218), the authors state: *"The difference in the methylation level at CpG sites between the mock and oxidative samples was taken as the hydroxymethylation level. The differential hydroxymethylation levels between the control and treatments were computed using the MethylKit v1.34.0 R package."*
   - In `oxRRBS`, naive subtraction ($\hat{p}_{5\text{hmC}} = \hat{p}_{\text{BS}} - \hat{p}_{\text{oxBS}}$) frequently yields **negative** $5\text{hmC}$ percentages due to binomial sampling noise whenever coverage is moderate (which is why specialized algorithms like `MLML` or `oxBS-MLE` are required), and `methylKit` models binomial count ratios ($C / (C+T)$), which cannot directly take a difference of two proportions ($\hat{p}_{\text{BS}} - \hat{p}_{\text{oxBS}}$) that can be negative without ad hoc truncation or count manipulation. Furthermore, the authors never state how many biological replicates were sequenced by `oxRRBS` (whether $n=1$ or $n=3$ per condition) or what minimum read depth (`10x`?) was required per CpG.
3. **Missing Equation in Section 4.5 and Typographical Errors in Figure Captions:**
   - In Section 4.5 (lines 202–204), the text reads: *"The activity for the TET enzymes was determined using the following formula: [blank line] where * Incubation time = 120 min and RFU = Relative Fluorescence Unit."* The equation itself was completely omitted from the manuscript!
   - In `Figure 4` and `Figure 6` captions (lines 63 and 75), the authors write: *"each black circle represents a CpG site with a **nonsignificant change (p < 0.05)** in 5hmC, while the red circles represent a CpG site with a **significant change at p < 0.05**"* (`nonsignificant` should be $p \ge 0.05$ or $q > 0.05$). Also in line 72, `TTS` (transcription termination site) is written instead of `TSS` (`≤1000 bp upstream TTS`).
4. **Absence of Sequencing Data Deposition:**
   - Despite generating genome-wide `oxRRBS` sequencing libraries in human leukemia cells, the Data Availability Statement (line 234) merely states *"The original contributions presented in this study are included in this article/the Supplementary Materials"*, with no NCBI GEO or SRA accession number provided.

#### Strengths
1. **Convergent Multi-Level Assays for `TET` Activation:** Combining `TET1/2/3` qRT-PCR across two timepoints (24 h, 48 h) and multiple concentrations with nuclear extract `TET` enzymatic activity and global `5hmC` quantification across two cell lines (`U937` and `HL60`) provides consistent evidence that curcumin and `DMC` upregulate `TET1/2` expression and global `5hmC`.
2. **Candid Discussion of Off-Target Oncogene Demethylation:** In the Discussion (line 160), the authors fairly point out that non-specific `TET` activation also affects promoters of leukemia-promoting oncogenes (`ANGPT1`, `PES1`, `ZNF222`).

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** Curcumin and `DMC` induce `TET1`, `TET2`, and (to a lesser extent) `TET3` mRNA expression, increase nuclear `TET` enzymatic activity, and increase global `5hmC` in `U937` and `HL60` leukemia cells. `[Well Supported]`
- **Claim 2:** Curcumin (`5 uM`) and `DMC` (`1 uM`) increase `5hmC` at 194 and 173 gene promoters, respectively, in `U937` cells. `[Moderately Supported]` — Supported by `oxRRBS`, though replicate numbers, sequencing depth, and `MLML` negative-value handling are undisclosed.
- **Claim 3:** CpG sites and gene promoters showing decreased `5hmC` after curcumin/DMC treatment (`154` and `171` promoters; `Tables 1–2`) represent "active demethylation" and re-expression of silenced genes. `[Methodologically Flawed]` — A decrease in `5hmC` alone does not distinguish true demethylation ($5\text{hmC} \to C$) from increased/persistent $5\text{mC}$ ($C \to 5\text{mC}$ or reduced $5\text{mC} \to 5\text{hmC}$ oxidation), and no promoter $5\text{mC}$ (`oxBS`) or target gene mRNA expression data are shown.

### 4. Reproducibility & Data Completeness
- **Data Availability:** Inadequate for a high-throughput sequencing study—no `GEO` or `SRA` accession is provided for the `oxRRBS` dataset.
- **Methods Completeness:** `TET1/2/3` primer sequences and bioinformatics package versions (`FastQC v0.11.9`, `Bismark v0.22.3`, `bowtie2 v2.4.4`, `methylKit v1.34.0`) are provided, but the `TET` activity formula (Section 4.5) and `oxRRBS` replicate/coverage details are missing.
</Blinded Review: TIME_ANON_0966>
